The work-up of patients with hypereosinophilia (HE) is complex. Following the recently revised World Health Organization criteria, we retrospectively reviewed 125 patients who were referred to us to exclude a neoplastic cause of HE (2003HE ( -2016. The clinical laboratory work-up confirmed secondary HE in 25 (20%) patients; myeloid/lymphoid neoplasms with rearrangements of PDGFRA (n = 9) or PDGFRB (n = 2) (9%); HE associated with a well-defined myeloid neoplasm in 8 (6%); and abnormal bone marrow and/or molecular genetic abnormalities consistent with chronic eosinophilic leukemia (CEL), not otherwise specified (NOS) in 21 (17%) patients. For the remaining 60 (48%) patients, a specific diagnosis was not identified, and 56 patients had HE related findings consistent with idiopathic hypereosinophilic syndrome (HES), while 4 patients who were asymptomatic. With a median follow up of 35.3 months (range, <1-104), patients with CEL, not otherwise specified (NOS) had a median OS of 26.1 months, significantly inferior to patients with idiopathic HES (not reached, P < .01). Thus, our experience in a single tertiary cancer center shows that the work-up of HE following WHO recommendations requires a multimodality-based approach; and a correct diagnosis determines risk stratification and proper patient management. However, the causes of HE remain unknown in approximately half of referred patients, indicating the need for further studies.
| INTRODUCTION
Eosinophilia is defined as an increase of eosinophils in peripheral blood or tissues above what is considered to be normal. A count of more than 0.5 × 10 9 /L eosinophils of blood is generally considered eosinophilia in adults. Hypereosinophilia (HE) is defined as a persistent prominent eosinophilia (absolute eosinophils ≥1.5 × 10 9 /L) in peripheral blood, and hypereosinophilic syndrome (HES) is HE in association with tissue/organ damage. 1 HE/HES may be the primary clinical or laboratory manifestation prompting referral to a hematology service to exclude a hematopoietic neoplasm or to seek treatment options.
The causes of HE/HES are broad that include reactive or neoplastic diseases. [1] [2] [3] Secondary/reactive HE is an expansion of eosinophils driven by an identifiable cause, such as parasitic infection, drug use, allergies, autoimmune diseases or a malignancy. In clonal hematopoietic neoplasms, eosinophils often bear the same molecular genetic aberrations as their progenitors. 1, 4 These clonal hematopoietic neoplasms can be further categorized into three large groups: (1) myeloid/lymphoid neoplasms with eosinophilia and rearrangements of PDGFRA, PDGFRB, FGFR1, or PCM1-JAK2, 5 (2) HE associated with another well-defined myeloid neoplasm, such as chronic myeloid leukemia (CML) or chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia with inversion of chromosome 16, 6 and (3) Chronic eosinophilic leukemia (CEL) not otherwise specified (NOS). 6, 7 CEL-NOS is currently classified as a form of myeloproliferative neoplasm (MPN) 8 and is a diagnosis that requires an exclusion of reactive HE as well as other well-defined molecular genetic or clinical entities.
In a significant number of patients, after extensive work-up, neither a reactive cause nor a clonal molecular genetic aberration is identified; these cases are placed under the "idiopathic" category. 9 The distinction between CEL-NOS and idiopathic HES can be challenging.
According to the WHO recommendation, 10, 11 the neoplastic nature of CEL-NOS is defined by the presence of increased blasts in BM or PB, or by demonstrating clonality of hematopoietic cells. In the past, clonality was determined mostly by chromosomal analysis or gene mutations known to occur in MPNs, such as JAK2V617F, MPL, CALR, or KIT.
However, MPNs with these mutations do not usually associate with HE. 12, 13 In the updated 2016 WHO classification system, mutations associated with myeloid neoplasms as detected by next generation sequencing (NGS) can be considered as evidence of clonality with the caveat that clonal hematopoiesis of indeterminate potential is also defined by the same mutations that occur frequently in the elderly. 14, 15 Thus, the identification of mutations alone do not define CEL, NOS.
Therefore, it is strongly recommended that all possible causes of reactive eosinophilia are excluded before making a diagnosis of CEL-NOS based solely on a molecular genetic abnormality. Recent evidence has shown that abnormal bone marrow (BM) morphology is valuable in establishing the presence of a clonal eosinophilic proliferation and it can be useful in discriminating CEL-NOS from reactive idiopathic HES. Thus, BM examination should be incorporated in the diagnostic algorithm of HE. 7 In this study, we retrospectively reviewed the diagnoses and classifications of 125 patients with HE who came to our institution over a period of 13 years for diagnostic assessment and clinical management.
We used a comprehensive diagnostic approach based on the WHO classification of eosinophilic disorders, 3, 11 supplemented by NGS results to rigorously exclude reactive causes and use different means to detect clonality, in combination with careful morphologic examination. The aims of this study were 2-fold: (1) To document the scope and distribution of the disorders that manifest as HE, (2) To show how a multimodality approach should be applied in the diagnostic work up and classification of these disorders and to demonstrate how this approach contributes to patient risk stratification, management, and prognosis.
| PATIENTS AND METHODS

| Patients
We included all patients who came to our institution, a tertiary cancer center, over a 13-year interval (2003-2016) for the evaluation of HE (≥1.5 × 10 9 /L). HES is defined as HE associated with "end-organ damage" according to the definition by the working group on eosinophil disorders. 16 Persistence of eosinophilia is often defined as a history of HE for at least 6 months; however, the 6-month rule might not be necessarily enforced if the diagnostic evaluation revealed sufficient diagnostic criteria of disease and there was a need to minimize organ damage caused by the eosinophilic infiltrate. The organ damage evaluation was performed through data collection including clinical presentations, biopsy proven eosinophilic infiltrate, bronchoalveolar lavage, endoscopic findings, CT/MRI Scan results, and lab values according to the guideline by the ICOG-EO working group on eosinophil disorders and syndromes 16 To diagnose a case as lymphocytic/T-cell variant HES, 2 an aberrant T cell population had to be identified by flow cytometry immunophenotypic analysis with or without monoclonal T-cell receptor gene rearrangements as assessed by polymerase chain reaction (PCR)-based methods.
BM aspiration and biopsy were performed in all patients due to the concern of an intrinsic or infiltrative disease process or the need to exclude such possibilities with certainty. Due to the time span of this study, some of the molecular genetic studies were not performed initially and NGS studies were performed retrospectively in cases for which DNA could be retrieved. If an underlying cause was not identified but HE persisted, following the diagnostic algorithm (Figure 1 ), such cases were considered to be "idiopathic. Immunohistochemical studies were performed using formalinfixed, paraffin-embedded tissue sections of BM aspirate clot or biopsy specimens as described previously. 7 The immunohistochemistry panel included antibodies specific for CD34, CD117, myeloperoxidase, terminal deoxynucleotidyl transferase, and mast cell tryptase; CD25 was assessed in a subset of cases.
| Flow cytometry immunophenotyping
Flow cytometry immunophenotyping (FCI) was performed as part of the routine work-up. If blasts were increased, a full FCI study would be performed to characterize the blasts. If no increase in blasts, BM samples were assessed routinely for aberrant mast cells and T cells.
Mast cell antibody panel included reagents specific for CD117, HLA-DR, CD2, and CD25; the T cell antibody panel included CD2, CD3, CD4, CD5, CD7, CD8, CD10, and CD26. In some cases, the neoplastic nature of the myeloid disorder was established when CD34+ myeloblasts were deemed aberrant using methods established previously for myelodysplastic syndromes 17 and minimal residual acute myeloid leukemia. 18 In our cohort study, flow Cytometry was performed in 76 out of 125 patients. T cell clonality was performed in 59 out of 125 patients. 18 out of 59 patients had T cell receptor rearrangement by PCR performed.
| Conventional karyotyping and FISH analysis
BM aspirate samples had conventional G-band karyotyping analysis using 24-hour unstimulated cultures as has been described. 19 
| Molecular studies
All molecular studies were performed on BM aspirate specimens.
Rearrangement of the T cell receptor was evaluated by PCR in accord with BIOMED-2 guideline. Qualitative nested RT-PCR analysis was performed on reverse-transcribed RNA from fresh BM for FIP1L1-PDG-FRA fusion transcript associated with a chromosome 4q12 interstitial deletion. Mutation-specific real-time PCR was performed to detect the KIT D816V mutation on extracted DNA in some cases. For cases within the most recent 6 years, NGS-based analysis was used for the detection of somatic mutations within 28 genes (including DNMT3A, JAK2, NPM1, FLT3, MPL, NRAS, KRAS, KIT, IDH1, IDH2, and TP53) and was performed on DNA extracted from fresh BM aspirate samples. 7, 13 Retrospectively, NGS was performed additionally on fresh frozen BM DNA samples of 25 patients using a panel consisting of 44 myeloid neoplasm-associated genes (sequencing >90% gene coding regions). 13 
| Data analysis
Data for categorical variables were described as the number of patients if not otherwise specified. Data for continuous variables were described as median and range. Fisher's exact test and univariate survival analysis were performed when applicable, using the statistical software of GraphPad Prism 7 (GraphPad Software, San Diego, CA). Significance level was determined when the P value is <.05 for all analyses.
3 | RESULTS
| Patients
A total of 125 patients who were referred to our institution for evaluation and/or clinical management of HE or HES were identified for the study period. There were 79 men and 46 women with a median age of 54 years (range, 15-89 years). Among these patients, 6 had slightly less than 1.5 ×10 9 /L eosinophils in PB, but had organ injury due to an eosinophilic infiltrate. The remaining 119 patients had ≥1.5
/L eosinophils in PB. These patients were evaluated following 
| Reactive/secondary eosinophilia
In 25 patients (16 M, 9 F), HE was reactive or secondary to an underlying cause (Suppl Table 2 ). These included parasite infections Three patients had HE associated with a T cell lymphoma. HE was the primary presentation with an absolute eosinophil count of 3.9, 17.7, and 13.6 × 10 9 /L, respectively. All 3 patients had low grade fever and lymphadenopathy. Lymph node biopsy specimens showed peripheral T cell lymphoma. Of note, 1 patient was treated for HES for 1 year with various agents, including corticosteroids and imatinib before a diagnosis of PTCL was confirmed. All 3 patients died of lymphoma. 1 of an unrelated cause (diabetes), 1 with severe cardiomyopathy due to HE-associated damage, and 1 with progression to AML.
| Eosinophilia associated with a well-defined myeloid neoplasm
Eight patients (4 M, 4 F) were diagnosed with a myeloid neoplasm (other than CEL-NOS) that was defined either by molecular genetic aberrations or distinctive clinicopathological features.
These included 1 patient with AML with inv (16) 
| Chronic eosinophilic leukemia-NOS vs idiopathic hypereosinophilic syndromes
There were 85 patients in this group (Figure 3 ). Clonal karyotypic abnormalities were identified in 9 patients. The abnormal karyotypes included a complex karyotype (n = 2), chromosome 7q abnormalities (n = 2), t(5;12)(q31;p13) not involving PDGFRB (n = 1), t(5;6) (q22;q21) (n = 1), trisomy 8 (n = 1), del(9)q (n = 1), and del(12)(q24.1q24.3) (n = 1). These 9 patients were classified as CEL-NOS. NGS was performed in 4 patients and there were no mutations (0/4).
Of the remaining 72 patients with no karyotype abnormalities or increased blasts, 4 patients had persistent asymptomatic HE that were classified as idiopathic HE. In the remaining 68 patients, NGS were performed in 39 (57%), and revealed a myeloid neoplasm associated mutation with a variant allele frequency (VAF) >10% in 8 patients (21%). These gene mutations included single mutations in JAK2 V617F (n = 1), JAK2 exon13 (n = 1), NRAS (n = 1), TET2 (2 mutations, n = 1), ASXL1 (n = 1); 2 mutations were found in 4 patients, including ASXL1 + EZH2 (n = 2), and TET2 + DNMT3A (n = 2).
A total of 13 (19%) patients had abnormal BM morphological findings that were consistent with a myeloid neoplasm associated with eosinophilia. Due to the lack of karyotypical abnormalities or defining mutations (NGS not available at the time), the pathologists gave various names. Five of these patients were called MPN with eosinophilia and 1 MDS/MPN with eosinophilia, 7 were given descriptive diagnoses for abnormal findings with deferral of the final diagnosis to the completion of molecular studies (n = 7). NGS performed on 11 of these 13 patients revealed mutations in 6, no mutations in 5. Of the latter 5 patients, 1 patient died at 26.1 months of infection, and one patient died within a month of multiorgan failure attributable to the eosinophilic disease. Two patients responded to imatinib and were alive at 2.1 and 54.8 months; and 1 patient had no response to steroids, and was lost to follow-up. On this retrospective review, these cases were grouped together with CEL-NOS due to prominent persistent HE and lack of characteristic molecular genetic abnormality of a specific subtype of MPN or MDS/MPN.
Fifty-six of 68 (82%) patients had unremarkable BM except for a slight increase in eosinophils. Mutation studies were performed in 27 of these patients and revealed gene mutations in 2 (7%) patients. A patient with TET2 (VAF 27%) mutation was a 71-year-old woman with a 13-year of history of HE associated with skin rash, and a pulmonary infiltrate, treated with hydroxyurea, steroids, and showed response to alemtuzumab. The patient died of unknown causes >20 years from initial diagnosis and 9 years after a mutation was identified.
The other patient who had TET2 (VAF 25%) and DNMT3A (VAF 15%) mutations was a 24-year-old man who had heart, brain and pulmonary injuries due to HE. He could not tolerate imatinib, but showed good response to prednisone; the patient was alive at 41 months after diagnosis.
The clinicopathological features of CEL-NOS (16 M, 5 F) were compared to idiopathic HES (29 M, 27 F)( Table 1) . Patients with CEL-NOS were older (P < .01); had a higher WBC (P < .01), higher peripheral blood eosinophils % and AEC (P < .01), lower Hb (P = .02); higher BM cellularity (P < .01) and higher % of eosinophils in the BM (P = .03).
The treatment for these patients was not uniform. Various agents were used in a given patient over the course of disease. The agents included hydroxyurea (for cytoreduction), corticosteroids with or without interferon, cyclosporine, methotrexate, and alemtuzumab.
Tyrosine kinase inhibitors, mostly imatinib and occasionally dasatinib, were used. Hypomethylating agents, single agent chemotherapy, and high-dose chemotherapy were also used in some patients when disease showed progression or was refractory to other treatment modalities. In patients with CEL-NOS, 11 patients received steroids, 12 patients received tyrosine kinase inhibitor (TKI) and 15 patients received non-TKI/steroid therapy including hydrea or campath.
Among the patients with idiopathic HES, 41 patients received steroids, 25 patients received TKI, and 25 patients also received nonsteroid/non-TKI therapy. One patient underwent hematopoietic stem cell transplant for uncontrollable idiopathic HES and another for CEL-NOS associated with 46,XX,t(5;6)(q22;q21). Total of seven patients received interferon, of which, 4 were indicated as pegylated interferon and three were not clear.
| Survival comparisons
The overall survival (OS) of patients was compared among 4 groups: Nonetheless, for cases in which a specific translocation can't be confirmed, a therapeutic trial with imatinib is recommended for patients with a poor response to corticosteroid therapy. 36 It is noteworthy that patients in this cohort only represent a subset of patients with "myeloid lymphoid neoplasm with a specific rearrangement" in the past 13 years at our institution since we did not include patients with eosinophils <1.5 × 10 9 /L or patients who were referred after TKI treatment.
There were 8 cases that were categorized as eosinophilia associated with a well-defined myeloid neoplasm; 6 of 8 cases were SM, and 1 of these patients also had CMML. Peripheral eosinophilia, >0.5 × 10 9 /L, is very common and reported in up to 28% of patients with SM. Conversely, in patients with SM with an associated hematological neoplasm (SM-AHN), about a quarter of patients are SM associated with HE (>1.5 × 10 9 /L), namely SM-MPN-eo. 37 Other disease entities with a primary manifestation as HE are uncommon, and we only found one case of inv (16) After a thorough and extensive work-up that excluded reactive/secondary eosinophilia, eosinophilia associated with a well-categorized hematopoietic neoplasm, cases with specific rearrangements, and CEL-NOS, no clear cause of HE that resulted in evidence of organ damage was identified in 40%-50% of patients, currently classified as idiopathic HES (Supporting Information Table 3 ). These patients often have a longstanding history of skin rash, gastrointestinal and pulmonary symptoms, muscle and joint pain, thromboembolic events, and severe forms included heart and brain involvement. BM is unremarkable except for increased eosinophils. It is possible that some of these "idiopathic" HES cases might be lymphocyte variant HES as a proper flow cytometry test was not performed in all cases. It is also likely that some of the idiopathic HES cases may be associated with an ill-defined autoimmune disease or allergy, but an autoantibody or characteristic features of a specific entity could not be revealed. HE has been reported in patients with IgG4-related disease, 40 which is a relatively recently recognized entity that was not vigorously evaluated in our patients. Finally, a clonal process that is not currently recognized as a myeloid neoplasm could have accounted for some of the cases being labeled as "idiopathic". The fact that some of these idiopathic HES responded to TKI therapy indicates an alteration/activation of tyrosine kinase activity due to a mechanism yet to be identified. We 
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